Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising
Novo Nordisk has filed a lawsuit against rival Eli Lilly in a U.S. federal court, accusing the American pharmaceutical company of misleading advertising by claiming its weight-loss drugs outperform Novo’s treatments. The lawsuit, filed...
Some U.S. Employers Plan to End Coverage of Weight-Loss Drugs as Costs Continue to Rise
Large employers in the United States are increasingly reconsidering coverage for GLP-1 weight-loss medications such as Wegovy, Zepbound, and Foundayo as growing demand continues to drive healthcare costs higher. According to recent surveys, around...
FDA Clears Novo Nordisk’s Wegovy Weight-Loss Pill, Marking Major Shift in Obesity Drug Market
The U.S. Food and Drug Administration has approved Novo Nordisk’s oral weight-loss pill containing 25 milligrams of semaglutide, giving the Danish drugmaker a crucial first-mover advantage in the race to bring a potent obesity...